Nautilus Biotechnology Inc (NAUT)

Currency in USD
2.590
+0.020(+0.78%)
Closed·
2.650+0.060(+2.32%)
·
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.4602.818
52 wk Range
0.6204.310
Key Statistics
Prev. Close
2.57
Open
2.77
Day's Range
2.46-2.818
52 wk Range
0.62-4.31
Volume
351.55K
Average Volume (3m)
298.57K
1-Year Change
277.9412%
Book Value / Share
1.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAUT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.000
Upside
+54.44%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Nautilus Biotechnology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Inc Earnings Call Summary for Q1/2026

  • Nautilus reported Q1 2026 EPS of -$0.12, beating forecast of -$0.17 by 29.41%; stock surged 11.63% in pre-market trading to $2.869.
  • Operating expenses declined 14% YoY to $16.1M, with R&D down 16% to $9.7M and G&A down 12% to $6.4M, demonstrating improved cost discipline.
  • Company maintains strong cash position of $143.4M with runway through 2027; expects ~$0.5M FY2026 revenue amid recognition delays.
  • Strategic commercialization initiatives underway with new sales hires; product launches planned for late 2026 targeting new therapeutic areas.
  • Key risks include geopolitical revenue delays, continued losses, and execution challenges in scaling commercialization amid competitive proteomics market.
Last Updated: 28/04/2026, 14:12
Read Full Transcript

Compare NAUT to Peers and Sector

Metrics to compare
NAUT
Peers
Sector
Relationship
P/E Ratio
−5.6x−1.5x−0.5x
PEG Ratio
−0.32−0.070.00
Price/Book
2.1x0.9x2.6x
Price / LTM Sales
-4.3x3.2x
Upside (Analyst Target)
54.4%55.4%48.8%
Fair Value Upside
Unlock33.6%7.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.000
(+54.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy4.00+54.44%2.50Maintain27/02/2026

Earnings

Latest Release
28/04/2026
EPS / Forecast
-0.12 / -0.17
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

2.460
ABOS
-2.38%
7.130
UGRO
+1.86%
9.300
OCC
-12.26%
2.120
AIFF
0.00%

FAQ

What Is the Nautilus Biotechnology (NASDAQ: NAUT) Share Price Today?

The Nautilus Biotechnology stock price today is 2.590 USD.

What Stock Exchange Does Nautilus Biotechnology (NAUT) Trade On?

Nautilus Biotechnology is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Nautilus Biotechnology?

The stock symbol (also called a 'ticker') for Nautilus Biotechnology is "NAUT."

What Is the Current Nautilus Biotechnology Market Capitalisation?

As of today, Nautilus Biotechnology (NASDAQ: NAUT) market cap is 327.800M USD.

What Is Nautilus Biotechnology's (NAUT) Earnings Per Share (TTM)?

The Nautilus Biotechnology EPS is currently -0.467 (Trailing Twelve Months).

When Is the Next Nautilus Biotechnology Earnings Date?

Nautilus Biotechnology's next earnings report will be released on 04/08/2026.

Is NAUT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nautilus Biotechnology moving averages and other technical indicators, the daily buy/sell signal for NAUT stock is Strong Sell.

How Many Times Has Nautilus Biotechnology Stock Split?

Nautilus Biotechnology has split 0 times. (See the NAUT stock split history page for full effective split date and price information.)

How Many Employees Does Nautilus Biotechnology Have?

Nautilus Biotechnology has 130 employees, based on their latest Companies House report.

What is the current trading status of Nautilus Biotechnology (NASDAQ: NAUT)?

As of 29/04/2026, Nautilus Biotechnology (NAUT) is trading at a share price of 2.590 USD, with a previous close of 2.570 USD. The stock has fluctuated within a day range of 2.460 USD to 2.818 USD, while its 52-week range spans from 0.620 USD to 4.310 USD.

What Is Nautilus Biotechnology (NAUT) Price Target According to Analysts?

The average 12-month price target for Nautilus Biotechnology is 4.000 USD, with a high estimate of 4 USD and a low estimate of 4 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +54.44% Upside potential.

What Is the NAUT Premarket Price?

NAUT's last pre-market stock price is 2.800 USD. The pre-market share volume is 31,970.000, and the stock has decreased by 0.230, or 8.950%.

What Is the NAUT After Hours Price?

NAUT's last after hours stock price is 2.650 USD, the stock has decreased by 0.060, or 2.320%.

Industry Spotlight

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.